发布求助
文献互助 智能选刊 最新文献

我们可以用疾病负担来预测转移性激素敏感前列腺癌的多西他赛活性吗?

IF 1 Q4 PHARMACOLOGY & PHARMACY
Expert Review of Precision Medicine and Drug Development Pub Date : 2020-02-12 DOI:10.1080/23808993.2020.1727739
M. Randhawa, Robert J. Jones
{"title":"我们可以用疾病负担来预测转移性激素敏感前列腺癌的多西他赛活性吗?","authors":"M. Randhawa, Robert J. Jones","doi":"10.1080/23808993.2020.1727739","DOIUrl":null,"url":null,"abstract":"One of the most important advances in the management of advanced prostate cancer in recent years, has been the utilization of drugs, previously reserved for those with metastatic castration-resista...","PeriodicalId":12124,"journal":{"name":"Expert Review of Precision Medicine and Drug Development","volume":"5 1","pages":"55 - 57"},"PeriodicalIF":1.0000,"publicationDate":"2020-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1080/23808993.2020.1727739","citationCount":"0","resultStr":"{\"title\":\"Can we use disease burden to predict docetaxel activity in metastatic hormone-sensitive prostate cancer?\",\"authors\":\"M. Randhawa, Robert J. Jones\",\"doi\":\"10.1080/23808993.2020.1727739\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"One of the most important advances in the management of advanced prostate cancer in recent years, has been the utilization of drugs, previously reserved for those with metastatic castration-resista...\",\"PeriodicalId\":12124,\"journal\":{\"name\":\"Expert Review of Precision Medicine and Drug Development\",\"volume\":\"5 1\",\"pages\":\"55 - 57\"},\"PeriodicalIF\":1.0000,\"publicationDate\":\"2020-02-12\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1080/23808993.2020.1727739\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Expert Review of Precision Medicine and Drug Development\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1080/23808993.2020.1727739\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Precision Medicine and Drug Development","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/23808993.2020.1727739","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

摘要

近年来晚期前列腺癌治疗中最重要的进展之一是药物的使用，这些药物以前只用于转移性去势抵抗性前列腺癌患者。
本文章由计算机程序翻译，如有差异，请以英文原文为准。
分享
查看原文 本刊更多论文
Can we use disease burden to predict docetaxel activity in metastatic hormone-sensitive prostate cancer?
One of the most important advances in the management of advanced prostate cancer in recent years, has been the utilization of drugs, previously reserved for those with metastatic castration-resista...
求助全文
通过发布文献求助，成功后即可免费获取论文全文。 去求助
来源期刊
Expert Review of Precision Medicine and Drug Development
Expert Review of Precision Medicine and Drug Development PHARMACOLOGY & PHARMACY-
CiteScore
2.30
自引率
0.00%
发文量
9
期刊介绍： Expert Review of Precision Medicine and Drug Development publishes primarily review articles covering the development and clinical application of medicine to be used in a personalized therapy setting; in addition, the journal also publishes original research and commentary-style articles. In an era where medicine is recognizing that a one-size-fits-all approach is not always appropriate, it has become necessary to identify patients responsive to treatments and treat patient populations using a tailored approach. Areas covered include: Development and application of drugs targeted to specific genotypes and populations, as well as advanced diagnostic technologies and significant biomarkers that aid in this. Clinical trials and case studies within personalized therapy and drug development. Screening, prediction and prevention of disease, prediction of adverse events, treatment monitoring, effects of metabolomics and microbiomics on treatment. Secondary population research, genome-wide association studies, disease–gene association studies, personal genome technologies. Ethical and cost–benefit issues, the impact to healthcare and business infrastructure, and regulatory issues.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信